Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: Secondary analyses of pooled data from the SCALE clinical development program

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 839-848

  Steinberg, William M ^a,b   Rosenstock, Julio ^c   Wadden, Thomas A ^d   Donsmark, Morten ^e   Jensen, Christine B ^e   DeVries, J Hans ^f  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Rockville Internal Medicine Group   (United States)

^c Dallas Diabetes and Endocrine Center at Medical City   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NOVO NORDISK A S   (Denmark)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; LIRAGLUTIDE; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; BODY MASS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GALLSTONE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ACUTE HEMORRHAGIC PANCREATITIS; BLOOD; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

AMYLASES; BIOMARKERS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPASE; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PANCREATITIS, ACUTE NECROTIZING; PREDIABETIC STATE; TREATMENT OUTCOME;

EID: 85021103533     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2684     Document Type: Conference Paper

References (33)

1. NauckMA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-2132
2. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125
3. Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57:1320-1324
4. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-797
5. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015;38: 1058-1066
6. Azoulay L, Filion KB, Platt RW, et al.; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 2016;176:1464-1473
7. NovoNordisk, Inc. Liraglutide 3.0mg forweight management. NDA 206-321 [Internet], 2014. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413318.pdf. Accessed 13 December 2016
8. Dunn SV. Tradjenta (linagliptin) new drug application medical review. In Center for Drug Evaluation and Research [Internet], 2011. Boehringer Ingelheim Pharmaceuticals, Inc. Available from http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/201280Orig1s000MedR.pdf. Accessed 13 December 2016
9. European Medicines Agency. Januvia (sitagliptin) European Public Assessment Report (EPAR) scientific discussion [Internet]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000722/WC500039057.pdf. Accessed 13 December 2016
10. Novartis PharmaGmbHN.Galvus (vildagliptin) 50 mg tablets. Summary of product characteristics [Internet], 2012. Available from http://www.ema .europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000771/WC500020327.pdf. Accessed 13 December 2016
11. Novo Nordisk A/S. Saxenda 6mg/mL. Summary of product characterisitics [Internet], 2016. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003780/WC500185786.pdf. Accessed 13 December 2016
12. Novo Nordisk, Inc. Saxenda (rDNA) injection. Prescribing information [Internet], 2015. Available from http://www.novo-pi.com/saxenda .pdf. Accessed 13 December 2016
13. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36: 741-744
14. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes 2014;38: 784-793
15. Victoza (liraglutide 6 mg/ml). Summary of product characteristics [Internet], 2014. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf. Accessed 13 December 2016
16. Victoza (liraglutide [rDNA origin] injection). Prescribing Information [Internet], 2015. Available from https://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022341lbl.pdf. Accessed 13 December 2016
17. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weightmanagement.NEngl JMed 2015;373:11-22
18. Wadden TA, Hollander P, Klein S, et al.; NN8022-1923 Investigators.Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes 2013;37:1443-1451
19. Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687-699
20. BlackmanA, FosterGD, ZammitG, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes 2016;40:1310-1319
21. Banks PA, Bollen TL, Dervenis C, et al.; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-111
22. Levey AS, Stevens LA, Schmid CH, et al.; CKDEPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 2011;155:408]. Ann Intern Med 2009;150:604-612
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
24. Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. Am J Gastroenterol 1994; 89:1863-1866
25. Steinberg WM, Nauck MA, Zinman B, et al.; LEADER Trial investigators. LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER trial. Pancreas 2014;43: 1223-1231
26. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-1290
27. Hou Y, Ernst SA, Heidenreich K, Williams JA. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am J Physiol Gastrointest Liver Physiol 2016;310:G26-G33
28. Koehler JA, Baggio LL, Cao X, et al. Glucagonlike peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2015;64:1046-1056
29. Gotfredsen CF,Mølck AM, Thorup I, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014; 63:2486-2497
30. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER SteeringCommittee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
31. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
32. Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretinbased drugs in patients with type 2 diabetes mellitus. JAMA Intern Med 2016;176: 1474-1481
33. Meier JJ, Rosenstock J. Therapy: gastrointestinal safety of incretin therapies: are we there yet? Nat Rev Gastroenterol Hepatol 2016;13: 630-632